Hints and tips:
...It attacked Thermo Fisher’s offer for being too low....
...Qiagen and Thermo Fisher did not immediately respond to requests to comment. Since the deal was announced, Qiagen’s stock price has increased by almost 25 per cent....
...Thermo Fisher convinced Qiagen’s board to take steps to reduce the chances that a deal would fail to secure shareholder support....
...But this year there have been just two takeovers of a US target company worth more than $5bn, according to figures prepared by Dealogic for the Financial Times — Thermo Fisher’s $7.2bn deal for drug ingredients...
...The press release noted debt financing would come from Goldman Sachs Bank USA and Goldman Sachs Lending Partners LLC. The bank also provided M&A advice to Thermo Fisher....
...The reverse Yankee comes from US-scientific supplies company, Thermo Fisher, which is set to offer investors the chance to buy €500m of its bonds with a maturity of seven years, and reopens the European...
...Last year it sold Phadia, an in-vitro allergy diagnostics company based in Sweden, to US-listed Thermo Fisher Scientific for an enterprise value of €2.47bn....
...Prior to joining Thermo in 1999 he had been chairman and chief executive of the American Stock Exchange....
International Edition